ArticleClinical Medicine Insights. Oncology2026
Combination Therapy, Drug Interactions, and Survival Outcomes in Metastatic Breast Cancer: A Pooled Analysis of Phase II Trials.
Article in Clinical Medicine Insights. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The relationship between regimen complexity, treatment sequencing, and survival outcomes in metastatic breast cancer (MBC) remains poorly characterized. Objectives: To quantify how treatment complexity, line of therapy, and baseline performance status (PS) differentially affect progression-free survival (PFS) and overall survival (OS), and to identify synergistic and antagonistic drug combinations across MBC phase II trials. Methods: A systematic PubMed search (1992-2022) identified 892 eligible studies comprising 1,088 treatment arms and 53,672 patients. Objective response rate (ORR), median PFS, and median OS were extracted per arm along with molecular subtype, treatment size, therapy type, line of therapy, and weighted ECOG PS. Drug-drug interactions were inferred using a null model of non-interacting agents. Results: Adding agents improved both PFS and OS, but the PFS benefit was approximately twice the OS benefit (effect size, ε Conclusion: Combination therapy confers a substantially larger benefit for PFS than OS and partially compensates for the treatment-line penalty in patients with pretreated MBC. Patient fitness appears to become increasingly critical for long-term survival and may help guide regimen planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.